@article{ATM17698,
author = {Xu Han and Marvin T. Nieman},
title = {Protease activated receptor 4: a backup receptor or a dark horse as a target in antiplatelet therapy?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {3},
year = {2017},
keywords = {},
abstract = {Platelets are the primary component of pathological arterial thrombi. As such, antiplatelet therapy is a key strategy for treatment of acute coronary syndrome (ACS). The recent publication by Wong and colleagues earlier this year reported a compound, BMS-986120, that targets protease activated receptor 4 (PAR4) in a reversible manner (1). BMS-986120 effectively inhibits thrombus formation with minimal bleeding complications in their animal model (1). Their paper demonstrates the potential of targeting PAR4 as a promising antiplatelet therapeutic approach (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/17698}
}